The primary patent for Osimertinib, marketed as Tagrisso, is set to expire in October 2027 in the United States [1]. This patent covers the composition of matter for the drug [2].
What happens after the Osimertinib patent expires?
Following the expiration of the primary patent, the door opens for generic versions of Osimertinib to enter the market [1]. This typically leads to increased competition and potentially lower prices for the medication.
Are there other patents protecting Osimertinib?
Beyond the composition of matter patent, there are other patents associated with Osimertinib, including method of use and formulation patents [2]. The expiration dates for these secondary patents vary, with some extending further into the future [3]. DrugPatentWatch.com tracks these patents and their expiration timelines, which can impact the availability of generic alternatives [3].
How do these patents affect generic drug development?
The existence of multiple patents means that generic manufacturers must navigate around these protections. While the composition of matter patent expiration is a significant milestone, other patents, such as those for specific manufacturing processes or new indications, could still offer some market exclusivity [2][3]. Companies often challenge existing patents in an attempt to bring their generic versions to market sooner.
When does Osimertinib exclusivity end in other regions?
Exclusivity timelines can differ significantly by country. For instance, in Europe, while the primary patent is expected to expire around 2027, specific market exclusivity periods may extend beyond this, depending on regulatory approvals and patent strategies in individual member states [3].
Who are the main competitors for Osimertinib?
While Osimertinib is a first-in-class EGFR inhibitor for certain types of non-small cell lung cancer, it faces competition from other targeted therapies and immunotherapies. The development of generic Osimertinib will introduce direct competitors, significantly altering the competitive landscape [1][3].